ENTITY
Ascentage Pharma Group Corp

Ascentage Pharma Group Corp (6855 HK)

42
Analysis
Health CareChina
Ascentage Pharma Group International operates as a clinical-stage biotechnology company. The Company develops novel therapies for cancers, hepatitis B virus, age-related diseases, and more. Ascentage Pharma Group International conducts businesses in China, the United States, and other countries.
more
03 Jan 2025 08:55

Pre-IPO Ascentage Pharma - The US Stock Listing Will Stimulate Future Growth Potential

​Ascentage aims to raise $100 million in US IPO, with potential valuation surpassing Hutchmed. Olverembatinib's outlook is certain. Catalyst is...

Logo
739 Views
Share
26 Nov 2024 08:55

Ascentage Pharma (6855.HK) - The Future Valuation Leap Is Worth Looking Forward To

Olverembatinib sales is expected to reach RMB240 million in 2024, RMB500 million in 2025. Reasonable market value is US$1.25-1.9 billion. Licensing...

Logo
309 Views
Share
17 Jun 2024 08:45

Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda - Finally on the Right Path

​Cooperation with Takeda saves Ascentage from survival problem, but self-building sales team remains a challenge. Investors eye anther deal with...

Logo
192 Views
Share
bullishVesync
09 Feb 2025 09:53

China Healthcare Weekly (Feb.9) - Vesync Is a High-Quality Company, VBP to Cover Retail Pharmacies

Promoting VBP in retail pharmacy may harm valuation.Biotech funding gap widens, investors advised to focus on leading companies. Vesync is a good...

Logo
363 Views
Share
04 Apr 2022 07:57

Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”

After continuous pullback, investors may lose interest in Innovent. However, it still has investment value based on pipeline, resources, R&D and...

Logo
311 Views
Share
x